SARATOGA, Calif., Sept. 21 /PRNewswire/ -- NovaShunt AG, a privately-held medical device company that designs, develops and markets proprietary, implantable automated fluid management systems today announced the appointment of Fiona Sander, MSME, to Director of Research & Clinical affairs.
Ms. Sander, who holds an advanced degree in mechanical engineering, has extensive experience developing medical devices, managing pre-clinical & clinical studies and contributing to the overall success of several start-up companies.
Most recently, Ms. Sander was Director of Research at BaroSense, Inc, a medical device company located in Menlo Park, CA specializing in the minimally invasive treatment of obesity. Prior to that, Ms. Sander was involved in Research & Development efforts at companies such as VNUS Medical Technologies, PercuSurge (Medtronic), EP Technologies (Boston Scientific) and RITA Medical. She holds several patents in the medical device field, and has worked with a broad range of technologies focusing on taking products from concept through to market launch.
"Fiona is an experienced technologist & manager with a proven track record of bringing successful medical devices to market," said Noel Johnson, Ph.D., President & CEO of NovaShunt. "Her broad technology experience and specific clinical study management skills makes her an ideal fit for NovaShunt."
"I am so pleased to accept the position as Director of Research & Clinical Affairs of NovaShunt," said Ms. Sander. "The technology that exists within NovaShunt will dramatically enhance the options available to patients with chronic fluid build-up issues. This technology, once successfully commercialized, will positively impact thousands of lives each year by improving clinical outcome and significantly enhancing quality of life.
NovaShunt was founded in 2004 to develop and manufacture automated implantable pump systems to move fluids around inside the body. The company's initial product line focuses on a large unmet clinical need to remove excess fluid that accumulates in the abdominal cavity in patients with a variety of illnesses including liver disease, congestive heart failure and some types of cancer. The company expects to have products available for clinical testing in 2007. NovaShunt is currently completing its first round of financing.
Headquartered in Zurich, Switzerland, NovaShunt AG is the leading innovator of a new category of patented technologies and products designed to remove chronic fluid build-up in the body. NovaShunt is focused on areas of unmet clinical need where its products can significantly improve clinical outcome and patient quality of life. For more information, please visit www.novashunt.com or email NovaShunt at firstname.lastname@example.org.
CONTACT: Noel L. Johnson, Ph.D., President & CEO of NovaShunt AG, Zurich,+41-44-360-52-03, or Saratoga, +1-408-656-9153, or email@example.com